{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:05:10Z","timestamp":1772276710554,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Capital Health Development Scientific Research Fund","award":["Grant No. 2022-2-4013"],"award-info":[{"award-number":["Grant No. 2022-2-4013"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-048"],"award-info":[{"award-number":["2022-PUMCH-B-048"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["XH-QN-012K"],"award-info":[{"award-number":["XH-QN-012K"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-001"],"award-info":[{"award-number":["2022-PUMCH-D-001"]}]},{"name":"National Key Research and Development Program of China","award":["2016YFC0901500"],"award-info":[{"award-number":["2016YFC0901500"]}]},{"name":"CAMS innovation fund for medical science","award":["CIFMS-2021-I2M-1-025"],"award-info":[{"award-number":["CIFMS-2021-I2M-1-025"]}]},{"name":"CAMS innovation fund for medical science","award":["CIFMS-2021-I2M-1-002"],"award-info":[{"award-number":["CIFMS-2021-I2M-1-002"]}]},{"name":"CAMS innovation fund for medical science","award":["CIFMS-2021-I2M-1-003"],"award-info":[{"award-number":["CIFMS-2021-I2M-1-003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071967"],"award-info":[{"award-number":["82071967"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11307-024-01953-7","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T17:01:41Z","timestamp":1726851701000},"page":"986-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemokine Receptor 4-Targeted PET\/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET\/CT"],"prefix":"10.1007","volume":"26","author":[{"given":"Qiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"1953_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046\u20131060","journal-title":"N Engl J Med"},{"key":"1953_CR2","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805\u20133812","journal-title":"J Clin Oncol"},{"key":"1953_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327:464\u2013477","journal-title":"JAMA"},{"key":"1953_CR4","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962\u20132972","journal-title":"Blood"},{"key":"1953_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101\u2013119","journal-title":"Mayo Clin Proc"},{"key":"1953_CR6","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"EA-O Zamagni","year":"2022","unstructured":"Zamagni EA-O, Barbato SA-O, Cavo MA-O (2022) How I treat high-risk multiple myeloma. Blood 139:2889\u20132903","journal-title":"Blood"},{"key":"1953_CR7","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C et al (2017) Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206\u2013e217","journal-title":"Lancet Oncol"},{"key":"1953_CR8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","volume":"83","author":"C Mesguich","year":"2014","unstructured":"Mesguich C, Fardanesh R, Tanenbaum L et al (2014) State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings. Eur J Radiol 83:2203\u20132223","journal-title":"Eur J Radiol"},{"key":"1953_CR9","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068\u20132076","journal-title":"Blood"},{"key":"1953_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","volume":"38","author":"R Haznedar","year":"2011","unstructured":"Haznedar R, Ak\u0131 SZ, Akdemir OU et al (2011) Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 38:1046\u20131053","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1953_CR11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A et al (2017) CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics 7:1589\u20131597","journal-title":"Theranostics"},{"key":"1953_CR12","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, Ngo H, Runnels J et al (2007) Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109:2708\u20132717","journal-title":"Blood"},{"key":"1953_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y et al (2020) Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging 47:537\u2013546","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1953_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A et al (2017) [(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values. Theranostics 7:205\u2013212","journal-title":"Theranostics"},{"key":"1953_CR15","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T et al (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49:4133\u20134144","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1953_CR16","doi-asserted-by":"publisher","first-page":"20211272","DOI":"10.1259\/bjr.20211272","volume":"95","author":"AS Shekhawat","year":"2022","unstructured":"Shekhawat AS, Singh B, Malhotra P et al (2022) Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-Pentixafor PET\/CT: comparison with (18)F-FDG PET\/CT. Br J Radiol 95:20211272","journal-title":"Br J Radiol"},{"key":"1953_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","volume":"35","author":"SA-O Kuyumcu","year":"2021","unstructured":"Kuyumcu SA-O, Isik EG, Tiryaki TO et al (2021) Prognostic significance of (68)Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to (18)F-FDG PET\/CT and laboratory results. Ann Nucl Med 35:1147\u20131156","journal-title":"Ann Nucl Med"},{"key":"1953_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S et al (2015) In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med 7:477\u2013487","journal-title":"EMBO Mol Med"},{"key":"1953_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","volume":"64","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Bezzi D et al (2023) New developments in myeloma treatment and response assessment. J Nucl Med 64:1331\u20131343","journal-title":"J Nucl Med"},{"key":"1953_CR20","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.7150\/thno.19119","volume":"7","author":"M Schottelius","year":"2017","unstructured":"Schottelius M, Osl T, Poschenrieder A et al (2017) [(177)Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics 7:2350\u20132362","journal-title":"Theranostics"},{"key":"1953_CR21","first-page":"754","volume":"63","author":"H H\u00e4nscheid","year":"2022","unstructured":"H\u00e4nscheid H, Schirbel A, Hartrampf P et al (2022) Biokinetics and dosimetry of (177)Lu-Pentixather. J Nucl Med 63:754\u2013760","journal-title":"J Nucl Med"},{"key":"1953_CR22","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.7150\/thno.45537","volume":"10","author":"T Osl","year":"2020","unstructured":"Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester HJ (2020) A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics 10:8264\u20138280","journal-title":"Theranostics"},{"key":"1953_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2967\/jnumed.115.167361","volume":"57","author":"K Herrmann","year":"2016","unstructured":"Herrmann K, Schottelius M, Lapa C et al (2016) First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57:248\u2013251","journal-title":"J Nucl Med"},{"key":"1953_CR24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","volume":"60","author":"S Maurer","year":"2019","unstructured":"Maurer S, Herhaus P, Lippenmeyer R et al (2019) Side effects of CXC-chemokine receptor 4-directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation. J Nucl Med 60:1399\u20131405","journal-title":"J Nucl Med"},{"key":"1953_CR25","doi-asserted-by":"publisher","unstructured":"Luyten K, Van Loy T, Cawthorne C et al (2021) D-Peptide-based probe for CXCR4-targeted molecular imaging and radionuclide therapy. Pharmaceutics 13. https:\/\/doi.org\/10.3390\/pharmaceutics13101619","DOI":"10.3390\/pharmaceutics13101619"},{"key":"1953_CR26","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2967\/jnumed.111.097733","volume":"52","author":"LE Woodard","year":"2011","unstructured":"Woodard LE, Nimmagadda S (2011) CXCR4-based imaging agents. J Nucl Med 52:1665\u20131669","journal-title":"J Nucl Med"},{"key":"1953_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/RLU.0000000000005194","volume":"49","author":"Q Yang","year":"2024","unstructured":"Yang Q, Zhang F, Hao Z et al (2024) Chemokine receptor 4-targeted PET\/CT with 68 Ga-pentixather detects more lesions than 68 Ga-pentixafor PET\/CT in multiple myeloma. Clin Nucl Med 49:592\u2013593","journal-title":"Clin Nucl Med"},{"key":"1953_CR28","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548","journal-title":"Lancet Oncol"},{"key":"1953_CR29","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"1953_CR30","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863\u20132869","journal-title":"J Clin Oncol"},{"key":"1953_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-010-1098-7","volume":"90","author":"GW Basak","year":"2011","unstructured":"Basak GW, Knopinska-Posluszny W, Matuszak M et al (2011) Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 90:557\u2013568","journal-title":"Ann Hematol"},{"key":"1953_CR32","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/cancers13081793","volume":"13","author":"S Ito","year":"2021","unstructured":"Ito S, Sato T, Maeta T (2021) Role and therapeutic targeting of SDF-1\u03b1\/CXCR4 axis in multiple myeloma. Cancers (Basel) 13:1793","journal-title":"Cancers (Basel)"},{"key":"1953_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30\u201334","journal-title":"Blood"},{"key":"1953_CR34","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","volume":"48","author":"O Westerland","year":"2021","unstructured":"Westerland O, Amlani A, Kelly-Morland C et al (2021) Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 48:2558\u20132565","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1953_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","volume":"32","author":"M Kircher","year":"2018","unstructured":"Kircher M, Herhaus P, Schottelius M et al (2018) CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med 32:503\u2013511","journal-title":"Ann Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01953-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01953-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01953-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:09:55Z","timestamp":1733954995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01953-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1953"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01953-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of Peking Union Medical College Hospital (ZS-2964) and registered at Clinicaltrial.gov (NCT05364177).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}